Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An antithrombin knockdown antibody (or anti-antithrombin antibody) is an antibody designed to bind and neutralize or deplete antithrombin (antithrombin III), a key natural anticoagulant that inhibits thrombin and factor Xa. In research settings, such as in vitro thrombin generation assays, polyclonal antibodies (e.g., sheep anti-human antithrombin antibodies) are used to experimentally deplete antithrombin levels to simulate hemostatic rebalancing. Therapeutically, anti-antithrombin antibodies and single-domain antibodies (nanobodies) are being explored as non-factor replacement therapies for hemophilia A, hemophilia B, and other rare coagulation factor deficiencies. By blocking the inhibitory activity of antithrombin, these antibodies promote thrombin generation and restore hemostasis in patients with bleeding diatheses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antithrombin knockdown antibody.